---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-003309"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:17:59.869274+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Olema reports FY2022 net loss of $104.8M, restructures to focus on OP-1250 Phase 3

## Summary
- Net loss of $104.8M for FY2022, vs $71.1M in FY2021.
- Cash and securities $204.4M at Dec 31, 2022, expected to fund operations into 2025.
- Workforce reduced by ~25% to focus on late-stage development of OP-1250; CBO leaving, CRO stepping down from role.
- Initiating first pivotal Phase 3 trial of OP-1250 in 2H 2023 for ER+/HER2- metastatic breast cancer.

## SEC filing metadata
- accession: 0001558370-23-003309
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/olma-20230309x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-003309
- JSON: https://secwatch.observer/filing/0001558370-23-003309.json
- Plain text: https://secwatch.observer/filing/0001558370-23-003309.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the quarter ended December 31, 2022 results: net income $26.2 million.
  - Period: the quarter ended December 31, 2022
  - Net income: $26.2 million
  - Result: reported results
  source text: Net loss was $26.2 million and $104.8 million for the quarter and year ended December 31, 2022, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income $104.8 million.
  - Period: the year ended December 31, 2022
  - Net income: $104.8 million
  - Result: reported results
  source text: Net loss was $26.2 million and $104.8 million for the quarter and year ended December 31, 2022, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.